MDXGHealthcare · BiotechnologyThe 5 Wall Street analysts covering MiMedx Group, Inc. hold a median 12-month price target of $8 — +80.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 15 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores MiMedx Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (38): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MDXG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +80.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Aug 2026 | Craig-Hallum | Maintains | Buy | $6.00 → $8.00 |
| 17 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $8.00 |
| 17 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 30 Apr 2026 | Citizens | Maintains | Market Outperform | $7.00 → $6.00 |
| 20 Apr 2026 | Citizens | Maintains | Market Outperform | — |
| 17 Apr 2026 | Craig-Hallum | Maintains | Buy | — |
| 23 Feb 2026 | Citizens | Initiates | Market Outperform | — |
| 17 Feb 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 20 Jan 2026 | Lake Street | Maintains | Buy | — |
| 17 Dec 2025 | Mizuho | Maintains | Outperform | — |
| 31 July 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 15 July 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 27 Feb 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 1 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 1 Aug 2024 | Craig-Hallum | Maintains | Buy | — |
| 2 July 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 1 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2024 | Lake Street | Initiates | Buy | — |
| 1 Mar 2024 | Mizuho | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDXG appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 16 Oct 2026, MiMedx Group, Inc. returned −33.2% against +16.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 53% of US stocks
Cheaper than 29% of US stocks
Cheaper than 9% of US stocks
Higher than 8% of US stocks
Higher than 14% of US stocks
Higher than 82% of US stocks
Higher than 19% of US stocks
Higher than 51% of US stocks
Higher than 49% of US stocks
Higher than 58% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MiMedx Group, Inc. has a market value of $683.0M and an enterprise value of $563.5M.
Revenue in the twelve months to 30 June 2026: $355.2M. The latest quarter shrank 34.7% year on year.
Net income over the same four quarters: $6.2M, a 1.8% net margin.
Diluted earnings per share, trailing twelve months: $0.04.
Free cash flow in the twelve months to 30 June 2026: $44.4M.
MiMedx Group, Inc. spent $14.6M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 117.0×; forward P/E: 34.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MiMedx Group, Inc. employs 808 people — $440K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MiMedx Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MiMedx Group announced it will report third-quarter 2026 operating and financial results after market close on October 28, 2026. Senior management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to review the results.
Why it matters — MDXG watchers can note when the company’s quarterly results and management review are scheduled.
The headline announces a favorable federal court ruling in which the court vacated FDA determinations that AXIOFILL is not minimally manipulated and should be classified as a biological product. This decision affects the regulatory classification matter concerning MIMEDX's AXIOFILL product.
Why it matters — For MDXG watchers, the court ruling could influence the regulatory status and market trajectory of a key product in the company's portfolio.
Law firm Kahn Swick & Foti is investigating the proposed acquisition of Sanara MedTech by MiMedx Group, seeking to determine whether the deal's price ($33.00 cash and 0.4735 MiMedx shares per Sanara share) and process were adequate.
Why it matters — The investigation into the proposed transaction could affect the terms or completion of MiMedx's acquisition of Sanara MedTech.
MiMedx Group announced that members of its senior management will participate in upcoming investor conferences. The company disclosed this via a press release dated September 8, 2026.
Why it matters — MDXG watchers would care because investor conference participation offers opportunities for management to present the company to investors and potentially raise its visibility in the financial community.
Law firm Kahn Swick & Foti, LLC announced it is investigating the adequacy of the price and process in the proposed acquisition of Sanara MedTech Inc. by MiMedx Group, Inc. Under the deal terms, Sanara shareholders would receive $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share.
Why it matters — The investigation introduces potential legal scrutiny and possible delays or revisions to MiMedx's proposed acquisition of Sanara MedTech, which MDXG watchers will want to monitor.
The 5 Wall Street analysts covering MiMedx Group, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering MiMedx Group, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MiMedx Group, Inc. 82 out of 100 across roughly 4,600 US stocks as at 15 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Oct 2026, MiMedx Group, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +80.6% from the last close, and Ticker Nerd's factor model ranks MiMedx Group, Inc. 82 out of 100 as at 15 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MiMedx Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDXG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $8 over the next 12 months.
MiMedx Group, Inc. returned -33.2% over the 12 months to 16 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026". MiMedx Group announced it will report third-quarter 2026 operating and financial results after market close on October 28, 2026. Senior management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to review the results.
MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products. MiMedx Group, Inc. develops, manufactures, and markets placental tissue allografts and other biomaterial products used in wound care, surgical, burn, orthopedic, spine, sports medicine, ophthalmic, and dental applications. Its portfolio includes products derived from human placental and umbilical cord tissues, designed to support tissue repair and biologic healing in clinical settings. The company serves hospitals, physicians, and other healthcare providers through a range of wound management and surgical solutions. MiMedx Group, Inc. operates as a specialized player in the broader regenerative medicine market, with products that are used across multiple therapeutic areas where biologic tissue processing and advanced treatment options are important.
CEO Mr. Joseph H. Capper · 808 employees · United States · https://www.mimedx.com
